CC
REGN icon

Centiva Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Centiva Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-407,100
Closed -$314M – 1951
2025
Q4 		$314M Buy
407,100
+7,100
+2% +$4.82M 2.56% 8
2025
Q3 		$225M Buy
400,000
+355,200
+793% +$201M 2.15% 8
2025
Q2 		$23.5M Buy
+44,800
New +$25M 0.38% 37
2025
Q1 		– Sell
-600
Closed -$427K – 2034
2024
Q4 		$427K Hold
600
– – 0.01% 915
2024
Q3 		$631K Buy
+600
New +$668K 0.01% 1088
2024
Q2 		– Sell
-3,600
Closed -$3.46M – 2432
2024
Q1 		$3.46M Buy
3,600
+1,100
+44% +$1.05M 0.08% 176
2023
Q4 		$2.2M Sell
2,500
-2,700
-52% -$2.22M 0.05% 329
2023
Q3 		$4.28M Sell
5,200
-1,600
-24% -$1.26M 0.09% 189
2023
Q2 		$4.89M Sell
6,800
-1,000
-13% -$771K 0.11% 185
2023
Q1 		$6.41M Buy
7,800
+3,300
+73% +$2.49M 0.16% 131
2022
Q4 		$3.25M Sell
4,500
-5,000
-53% -$3.69M 0.09% 226
2022
Q3 		$6.54M Buy
9,500
+2,500
+36% +$1.57M 0.12% 115
2022
Q2 		$4.14M Sell
7,000
-1,000
-13% -$650K 0.1% 183
2022
Q1 		$5.59M Buy
8,000
+6,900
+627% +$4.37M 0.11% 146
2021
Q4 		$695K Buy
+1,100
New +$676K 0.01% 713
2019
Q2 		– Sell
-6,400
Closed -$2.63M – 498
2019
Q1 		$2.63M Buy
6,400
+3,800
+146% +$1.56M 0.18% 93
2018
Q4 		$971K Buy
+2,600
New +$952K 0.08% 144

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Centiva Capital's REGN Position: Q2 2026 in Review

Centiva Capital reduced its Regeneron Pharmaceuticals (REGN) stake by 97% in Q2 2026, selling an estimated $9.67M and leaving 408 shares worth $254K. The position accounts for ﹤0.01% of the portfolio, ranked #1261.

Centiva Capital first reported a position in REGN in Q4 2018 and has held it in 19 quarters since. The position peaked at $11.3M in Q1 2026. 1,340 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Centiva Capital held 408 shares of Regeneron Pharmaceuticals worth $254K as of Q2 2026.
  • Centiva Capital sold 14,202 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $9.67M.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Centiva Capital's portfolio in Q2 2026, its #1261 holding.
  • Centiva Capital first reported a position in Regeneron Pharmaceuticals in Q4 2018 and has held it in 19 quarters since.
  • Centiva Capital's Regeneron Pharmaceuticals position peaked at $11.3M in Q1 2026.
  • 1,340 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Centiva Capital's 13F filing for Q2 2026, filed 13 Aug 2026.